Mylan assures India it won't dismiss domestic market with Agila buy

Mylan ($MYL) has let authorities in India know that if they approve its planned $1.6 billion deal to buy Strides Arcolab's sterile injectables unit, Agila Specialties, it intends to more than triple the sterile injectable production aimed at the Indian market. The plans are outlined in a filing with India's Department of Industrial Policy and Promotion (DIPP), which has delayed approval of the deal over concerns that Mylan might slight the domestic market once the deal is complete. Story | More

Suggested Articles

Turns out Procter & Gamble didn’t want Pfizer’s consumer health unit after all. But it did want Merck KGaA’s.

Private equity firm, in exclusive talks with Sanofi, says it'll invest to pump up Zentiva into an "independent European generics leader."

With suitor Takeda circling Shire, the Dublin-based target has pulled off a deal of its own.